Researchers report how HER2 breast cancer cells adopt a strategy to resist clearance by redirected lymphocytes. Findings evidence that the disruption of interferon-gamma signaling confers resistance to these immunotherapies and promotes disease progression. These results could help to potentiate future immune-based strategies and more precisely identify those patients who would be most likely to benefit from them.
